Acute myeloblastic leukemia with maturation
MONDO:0020320An acute myeloid leukemia (AML) characterized by blasts with evidence of maturation to more mature neutrophils. (WHO, 2001)
Also known as: AML M2, AML with maturation, FAB M2, M2 acute granulocytic leukaemia, M2 acute granulocytic leukemia, M2 acute myeloblastic leukaemia, M2 acute myeloblastic leukaemia with maturation, M2 acute myeloblastic leukemia
3105 clinical trials for this condition and its sub-types, 26 tagged with Acute myeloblastic leukemia with maturation itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Can a Platelet-Boosting drug speed recovery for older leukemia patients?
Disease control CompletedThis phase II trial investigates whether eltrombopag, a drug that stimulates platelet production, can help older adults with acute myeloid leukemia (AML) recover their platelet counts faster after initial chemotherapy. Older patients often experience slow platelet recovery, which…
Phase 2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Could a targeted drug keep AML in check?
Disease control CompletedThis phase III trial tests whether the drug tipifarnib can prevent acute myeloid leukemia (AML) from coming back in patients who are already in remission. Participants include adults over 60 in first remission, those in second or later remission, or those who achieved remission a…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Generic azacitidine tablet tested against Brand-Name onureg in AML patients
Disease control CompletedThis study compared a generic azacitidine tablet to the brand-name drug Onureg in 32 adults with acute myeloid leukemia (AML) who are in remission. Participants took a single dose of each drug under fasting conditions to see if the generic version is absorbed similarly. The goal …
Phase 1 • Sponsor: Hikma Pharmaceuticals LLC • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Can AML patients give their own transfusions at home?
Symptom relief CompletedResearchers at Rigshospitalet in Denmark are testing whether adults newly diagnosed with acute myeloid leukemia can safely measure their own blood counts and give themselves blood and platelet transfusions at home. The study trains and certifies 22 participants to use a home bloo…
Sponsor: Rigshospitalet, Denmark • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Small study checks kidney and race impact on transplant drug
Knowledge-focused CompletedThis study looked at how kidney function and race/ethnicity affect the drug treosulfan in 20 patients with AML or MDS getting a stem cell transplant. The goal was to find safe doses for those with kidney problems. It was a small, early-phase study that did not test a new treatmen…
Phase 1 • Sponsor: medac GmbH • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Why do some Low-Risk leukemia patients relapse? scientists look to bone marrow cells for answers
Knowledge-focused CompletedThis completed study looked at bone marrow stem cells from 70 adults with acute myeloid leukemia (AML) who had a favorable genetic marker (NPM1 mutation). The goal was to understand why more than half of these patients still relapse despite having a good prognosis. Researchers an…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
AI boosts cancer diagnosis speed in small study
Knowledge-focused CompletedThis study tested whether artificial intelligence (AI) can help doctors diagnose a rare blood cancer called acute promyelocytic leukemia (APL) more quickly and accurately. Ten doctors reviewed bone marrow samples with and without AI assistance. The goal was to see if AI improves …
Sponsor: Harvard Medical School (HMS and HSDM) • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC